3-year update of neoadjuvant atezolizumab plus chemotherapy in patients with resectable non-small cell lung cancer

被引：3
|
作者：
Henick, Brian S.
Gainor, Justin F.
Awad, Mark M.
Chiuzan, Codruta
Izard, Stephanie
Georgis, Yohanna
Koch, Peter D.
Garofano, Robert F.
Wong, Cheryl V.
Saqi, Anjali
Grindheim, Jessica M.
Schulze, Katja
Rizvi, Naiyer A.
Izar, Benjamin
Taylor, Alison M.
Shu, Catherine A.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT217
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT217
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Real-world clinical outcomes of neoadjuvant chemotherapy plus pembrolizumab or tislelizumab in resectable non-small cell lung cancer
    Hu, Yan
    Ren, Siying
    Wu, Fang
    Liu, Wenliang
    RESPIROLOGY, 2024, 29 : 41 - 41
  • [32] Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).
    Rusch, Valerie W.
    Chaft, Jamie E.
    Johnson, Bruce
    Wistuba, Ignacio Ivan
    Kris, Mark G.
    Lee, Jay M.
    Bunn, Paul A.
    Kwiatkowski, David J.
    Reckamp, Karen L.
    Finley, David J.
    Haura, Eric B.
    Waqar, Saiama Naheed
    Doebele, Robert Charles
    Garon, Edward B.
    Blasberg, Justin
    Nicholas, Alan
    Schulze, Katja
    Phan, See-Chun
    Gandhi, Mayank
    Carbone, David Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
    Besse, B.
    Adam, J.
    Cozic, N.
    Chaput-Gras, N.
    Planchard, D.
    Mezquita, L.
    Remon Masip, J.
    Lavaud, P.
    Naltet, C.
    Gazzah, A.
    de Montpreville, V. Thomas
    Ghigna, M. -R.
    Mussot, S.
    Fadel, E.
    Mabille, L.
    Duchemann, B.
    Barlesi, F.
    Soria, J-C.
    Caramella, C.
    Mercier, O.
    ANNALS OF ONCOLOGY, 2020, 31 : S794 - S795
  • [34] Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 Study
    Presley, C.
    Owen, D. H.
    Nicholas, A.
    Hilz, S.
    Oezkan, F.
    Chaft, J. E.
    Toloza, E. M.
    Haura, E. B.
    Patterson, A.
    Waqar, S. N.
    Bunn, P.
    Johnson, B. E.
    Kris, M. G.
    Lee, J. M.
    Kwiatkowski, D. J.
    Wistuba, I. I.
    Schulze, K.
    Johnson, A.
    Rusch, V. W.
    Carbone, D. P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S275 - S276
  • [35] Neoadjuvant Immuno-Chemotherapy in Resectable Non-Small Cell Lung Cancer - A Retrospective Cohort Study
    Verma, S.
    Vincent, M. D.
    Black, M.
    Nayak, R.
    Cecchini, M.
    Malthaner, R.
    Raphael, J.
    Inculet, R.
    Fortin, D.
    Blanchette, P.
    Kuruvilla, S.
    Qiabi, M.
    Younus, J.
    Breadner, D. A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S546 - S546
  • [36] Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)
    Rusch, V.
    Chaft, J.
    Johnson, B.
    Wistuba, I.
    Kris, M.
    Lee, J.
    Bunn, P., Jr.
    Kwiatkowski, D.
    Reckamp, K.
    Finley, D.
    Haura, E.
    Wagar, S.
    Doebele, R.
    Garon, E.
    Blasberg, J.
    Nicholas, A.
    Schulze, K.
    Phan, S.
    Gandhi, M.
    Carbone, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S369 - S369
  • [37] Phase II study of Neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer
    Ramnath, N
    Sommers, E
    Robinson, L
    Nwogu, C
    Sharma, A
    Cantor, A
    Bepler, G
    CHEST, 2005, 128 (05) : 3467 - 3474
  • [38] Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer
    Livingston, RB
    ANNALS OF ONCOLOGY, 1998, 9 : 4 - 4
  • [39] Neoadjuvant chemotherapy with docetaxel in non-small cell lung cancer
    Mattson, K
    SEMINARS IN ONCOLOGY, 2001, 28 (03) : 33 - 36
  • [40] Neoadjuvant chemotherapy for advanced non-small cell lung cancer
    Pereira, JR
    Minamoto, H
    Ghefter, MC
    Paschoalini, M
    Martins, SJ
    Ikari, FK
    Nikaedo, SM
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 639 - 642
12345